CBP501, a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) – results of two phase I/II studies. 2009 AACR-NCI-EORTC

Bruno Bastos

CBP501, a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) – results of two phase I/II studies. 2009 AACR-NCI-EORTC

Bruno Bastos

Research output: Contribution to conference › Presentation

Original language	American English
State	Published - Nov 2009
Event	Molecular Targets and Cancer Therapeutics Conference - Boston, MA Duration: Nov 1 2009 → …

Conference

Conference	Molecular Targets and Cancer Therapeutics Conference
Period	11/1/09 → …

Disciplines

Medicine and Health Sciences

Cite this

@conference{60abc7b8251a4425b5731f5c04d139e3,

title = "CBP501, a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) – results of two phase I/II studies. 2009 AACR-NCI-EORTC",

author = "Bruno Bastos",

year = "2009",

month = nov,

language = "American English",

note = "Molecular Targets and Cancer Therapeutics Conference ; Conference date: 01-11-2009",

}